SHARE

ASK: Help to make CE-marked medical device scalable

18th April 2020

Albus Health seeking partners for COVID-19 symptom monitoring device

Albus Health looking for partners to help scale their CE marked non-contact device that can monitor COVID-19 symptoms in patients.

Albus Health has developed a small non-contact table-top device that automatically monitors respiratory symptoms (including cough and respiratory rate) and environmental metrics at home without the patients having to do or wear anything. Being plug-and-play, passive, non-contact and connected to the internet, this is suitable for all age groups, suitable for people of all ages, regardless of their background, technical proficiency or geographical location.

This device is CE marked and has been used to monitor severe asthma in patients for over a year.

Researchers and clinicians around the world have highlighted the need to monitor symptoms at home without coming into the hospital or being in contact with a healthcare professional – Albus’ technology is ideal for this, especially when self-isolation and social distancing is required.

This could help identify those who need hospital admissions (vs those who can get better at home) and diagnosis of COVID-19 from conditions such as flu.

Albus Health is looking for resources and funding to make their device scalable. In particular, they are looking to hear from organisations and individuals in Europe with expertise in areas of time series analysis, full-stack developers and redesigning for bulk manufacturing.

For more information, pleaese contact
Mikesh Udani

| |
Contact

ASK: Research contributors needed for CON-VICE study

ASK: Research contributors needed for CON-VICE study

University of Luxembourg needs European researchers to get in touch

Find out more

OFFER: Funding available for COVID-19 research

OFFER: Funding available for COVID-19 research

Fondation Air Liquide are looking to fund European projects

Find out more

ASK: Supporting the immunocompromised

ASK: Supporting the immunocompromised

Partners sought to advance neutralising antibody

Find out more